We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings In Line: Headquartered in Houston, TX, Enterprise Products Partners L.P. (EPD - Free Report) reported adjusted fourth-quarter earnings of 54 cents per unit, same as the Zacks Consensus Estimate.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate of earnings for the quarter has been unchanged in the past seven days.
Enterprise Products has an impressive earnings surprise history. The partnership managed to beat the Zacks Consensus Estimate in three of the last four quarters, the average positive earnings surprise being roughly 9.85%.
Enterprise Products Partners L.P. Price and EPS Surprise
Revenues Beat: Revenues of $8,005.3 million surpassed the Zacks Consensus Estimate of $7,973 million.
Key Stats: Adjusted distributable cash flow was recorded at $1.6 billion, up 12% year over year and provided coverage of 1.7x. The partnership has retained $654 million of distributable cash flow.
Notably, NGL, crude oil, refined products & petrochemical pipeline volumes were recorded at 6.9 million barrels per day level in the fourth quarter of 2019.
Check back later for our full write up on this Enterprise Products earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Enterprise (EPD) Q4 Earnings Meet, Revenues Beat Estimates
Earnings In Line: Headquartered in Houston, TX, Enterprise Products Partners L.P. (EPD - Free Report) reported adjusted fourth-quarter earnings of 54 cents per unit, same as the Zacks Consensus Estimate.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate of earnings for the quarter has been unchanged in the past seven days.
Enterprise Products has an impressive earnings surprise history. The partnership managed to beat the Zacks Consensus Estimate in three of the last four quarters, the average positive earnings surprise being roughly 9.85%.
Enterprise Products Partners L.P. Price and EPS Surprise
Enterprise Products Partners L.P. price-eps-surprise | Enterprise Products Partners L.P. Quote
Revenues Beat: Revenues of $8,005.3 million surpassed the Zacks Consensus Estimate of $7,973 million.
Key Stats: Adjusted distributable cash flow was recorded at $1.6 billion, up 12% year over year and provided coverage of 1.7x. The partnership has retained $654 million of distributable cash flow.
Notably, NGL, crude oil, refined products & petrochemical pipeline volumes were recorded at 6.9 million barrels per day level in the fourth quarter of 2019.
Zacks Rank: Currently, Enterprise Products has a Zacks Rank #3 (Hold) but that could change following its third-quarter 2019 report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Enterprise Products earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>